Revascularization Strategies in Patients With Non-ST-Segment Elevation Acute Coronary Synd
MILESTONE STUDY is dedicated to problems connected with patients with multivessel coronary artery disease and/or with left main narrowing who present symptoms of acute ischemia. For such kind of patients according to current ACC/AHA guidelines CABG (surgical revascularization) is recommended as a treatment method. In c
| Condition(s) | Multivessel Coronary Artery Disease, Acute Coronary Syndrome |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | MILESTONE STUDY is dedicated to problems connected with patients with multivessel coronary artery disease and/or with left main narrowing who present symptoms of acute ischemia. For such kind of patients according to current ACC/AHA guidelines CABG (surgical revascularization) is recommended as a treatment method. In comparison with CABG, recent studies have shown that PCI (percutaneous coronary intervention) is associated with a lower rate of periprocedural adverse events and similar long term event-free survival in patients with left main disease. Our latest non randomized registry and randomized LEMANS study, comparing LMCA (left main coronary artery) stenting with CABG confirmed above findings. LEMANS ACS (acute coronary syndrome) retrospective registry of patients with UPLMCA (unprote |
| Who can participate | Inclusion Criteria: Subjects must meet ALL of the inclusion criteria to be considered for the trial. If ANY of the exclusion criteria are met, the subject is excluded from the trial and cannot be randomized. * Age over 18 years, * Written patient consent, * Acute Coronary Syndrome without ST-segment elevation of high, intermediate and low risk, including NSTEMI and unstable angina requiring urgent (within 72 hours) invasive strategy, * Qualification for invasive treatment, * Multivessel coronary disease, defined as angiographic narrowing \>50%DS on investigator's visual assessment in at least two major coronary artery territories (RCA, LAD, LCX), including involvement of the proximal segment of the left anterior descending artery or three-vessel disease with a Syntax Score \< 33. Intermedi |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | American Heart of Poland |
| Locations | Chrzanów, Malopolska, Poland; Bielsko-Biala, Silesian Voivodeship, Poland; Dąbrowa Górnicza, Silesian Voivodeship, Poland; Ustroń, Silesian Voivodeship, Poland; Kędzierzyn-Koźle, Poland; Tychy, Poland (+1 more sites) |
| Start date | 2025-08-25 |
| NCT ID | NCT01311323 |
| Official listing | https://clinicaltrials.gov/study/NCT01311323 |